Why Kite Pharma Soared 64.8% in August
Shares of Kite Pharma (NASDAQ: KITE), a clinical-stage biotech focused on chimeric antigen receptor T-cell (CAR-T therapy), skyrocketed 65% in August, according to data from S&P Global Market Intelligence. The huge jump was caused by the news that Kite accepted a buyout offer from biotech giant Gilead Sciences (NASDAQ: GILD).
Gilead Sciences agreed to acquire Kite for $11.9 billion, or $180 per share. That buyout price represented a 29% premium to its closing price prior to the announcement.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€77.06
0.640%
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Gilead Sciences Inc.
As a result the target price of 85 € shows a slightly positive potential of 10.3% compared to the current price of 77.06 € for Gilead Sciences Inc.
